Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase II drugs for Basal Cell Carcinoma (Basal Cell Epithelioma) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lixadesiran + pixofisiran’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lixadesiran + pixofisiran overview

STP705 is under development for the treatment of cutaneous squamous cell carcinoma in situ (isSCC, Bowen's disease), metastatic liver cancer, facial squamous cell skin cancer in situ (isSCC), basal cell carcinoma, primary sclerosing cholangitis, keloid scar less healing, skin hypertrophic scars, abdominal obesity. The drug is a siRNA and is administered through intradermal injection, topically as cream, intra-tumorally and subcutaneously. Drug has two small interfering RNAs (pixofisiran INN and lixadesiran INN) that target TGF-beta 1 and COX-2, respectively and is being developed based on PNP platform.

It was under development for the treatment of pulmonary fibrosis, kidney fibrosis, wounds, pancreatic cancer, non-alcoholic steatohepatitis, cholangiocarcinoma, hepatocellular carcinoma and bladder cancer.

Sirnaomics overview

Sirnaomics, is a healthcare service provider that discovers and develops therapeutics. The company’s products portfolio includes siRNA and niRNA. It offers product development, preclinical programs, clinical development services and others. Sirnaomics provides its products for therapeutic programs such as lung cancer, breast cancer, organ transplantation, skin hypertrophic scars, colorectal cancer, influenza A, HPV and cervical cancer, ocular neo-vascularization, spinal cord injury, EBOLA infection and giloblastoma, among others. The company also provides active pharmaceutical ingredients as therapeutic agents for treatment of various critical human diseases. It has its presence in the US and China. the company is headquartered in Gaithersburg, Maryland, the US.

For a complete picture of Lixadesiran + pixofisiran’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.